XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss available to common stockholders $ (19,937) $ (23,724)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 551 490
Reduction in the carrying amount of right-of-use assets 233 130
Change in fair value of warrants, tranche and SEPA liability 2,311 (660)
Change in fair value of Initial OrbiMed Warrants and revenue base redemption liabilities (790) 0
Change in fair value of contingent earnout liability (12,061) (19,904)
Non-cash interest expense 377 0
Loss on equity issuance 0 5,691
Extinguishment of tranche liability 0 (1,520)
Stock-based compensation expense 3,744 402
Loss on disposal of fixed assets 18 60
Amortization of debt issuance costs 434 0
Milestone payments to Dynavax 0 1,000
Changes in operating assets and liabilities:    
Accounts receivable (1,358) (1,477)
Inventory (1,455) (158)
Prepaid expenses (2,323) 1,041
Deposits 43 0
Operating lease liabilities (238) (202)
Trade payables and accrued liabilities (4,685) (2,570)
Net cash used in operating activities (35,136) (41,401)
Cash flows from investing activities:    
Purchases of property and equipment (295) (216)
Milestone payments to Dynavax 0 (1,000)
Net cash used in investing activities (295) (1,216)
Cash flows from financing activities:    
Proceeds from the issuance of preferred stock 0 9,189
Proceeds from the issuance of common stock 12,586 0
Proceeds from exercise of preferred stock warrants 0 9,630
Proceeds from Business Combination 0 36,854
Offering costs related to Business Combination 0 (1,116)
Debt issuance costs (2,593) 0
Proceeds from the issuance of debt 25,000 0
Payments on finance lease liabilities (65) (65)
Proceeds from the exercise of stock options for common stock 14 94
Net cash provided by financing activities 34,942 54,586
(Decrease) increase in cash, cash equivalents and restricted cash (489) 11,969
Cash, cash equivalents and restricted cash, beginning of period 12,127 9,664
Cash, cash equivalents and restricted cash, end of period 11,638 21,633
Supplemental disclosures of cash flow information:    
Fair value of warrants issued with OrbiMed debt 325 0
Fair value of revenue base redemption liability related to OrbiMed debt 425 0
Fair value of warrants issued with Series B-2 preferred stock 0 14,701
Right-of-use assets obtained in exchange for new operating lease liabilities 464 0
Transfer of warrant liability to preferred stock upon exercise of warrants $ 0 $ 12,082